• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Observational, retrospective real-world evidence study demonstrates safety, performance and usefulness of antimicrobial central venous catheters.观察性、回顾性真实世界证据研究表明抗菌中央静脉导管的安全性、性能和有用性。
J Int Med Res. 2024 Sep;52(9):3000605241279236. doi: 10.1177/03000605241279236.
2
Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults.用于降低成人中心静脉导管相关感染的导管浸渍、涂层或粘结
Cochrane Database Syst Rev. 2016 Mar 16;3(3):CD007878. doi: 10.1002/14651858.CD007878.pub3.
3
Antimicrobial dressings for the prevention of catheter-related infections in newborn infants with central venous catheters.用于预防新生儿中心静脉导管相关感染的抗菌敷料。
Cochrane Database Syst Rev. 2016 Mar 23;3(3):CD011082. doi: 10.1002/14651858.CD011082.pub2.
4
Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).使用牛磺罗定 - 柠檬酸盐封管溶液预防成年中性粒细胞减少血液学患者中心静脉导管感染：一项随机、双盲、安慰剂对照试验（TAURCAT）
Trials. 2018 May 2;19(1):264. doi: 10.1186/s13063-018-2647-y.
5
Peripherally inserted central catheters are associated with lower risk of bloodstream infection compared with central venous catheters in paediatric intensive care patients: a propensity-adjusted analysis.外周置入中心静脉导管与中心静脉导管相比，与儿科重症监护患者的血流感染风险较低：一项倾向调整分析。
Intensive Care Med. 2017 Aug;43(8):1097-1104. doi: 10.1007/s00134-017-4852-7. Epub 2017 Jun 5.
6
Comparison of Rates of Central Line-Associated Bloodstream Infections in Patients With 1 vs 2 Central Venous Catheters.比较 1 根与 2 根中心静脉导管患者的中心静脉导管相关血流感染发生率。
JAMA Netw Open. 2020 Mar 2;3(3):e200396. doi: 10.1001/jamanetworkopen.2020.0396.
7
Performance and safety of PowerPICC catheters and accessories: a prospective observational study.PowerPICC 导管及其附件的性能和安全性：一项前瞻性观察研究。
BMJ Open. 2024 Sep 30;14(9):e081288. doi: 10.1136/bmjopen-2023-081288.
8
The microbiological and clinical outcome of guide wire exchanged versus newly inserted antimicrobial surface treated central venous catheters.导丝交换的抗菌表面处理中心静脉导管与新插入的抗菌表面处理中心静脉导管的微生物学和临床结果。
Crit Care. 2013 Sep 3;17(5):R184. doi: 10.1186/cc12867.
9
Comparison of microbial colonization rates between central venous catheters and peripherally inserted central catheters.中心静脉导管与经外周中心静脉置管的微生物定植率比较。
Antimicrob Resist Infect Control. 2023 Aug 7;12(1):74. doi: 10.1186/s13756-023-01285-1.
10
Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population.在儿科烧伤患者中引入米诺环素和利福平抗菌涂层导管后导管相关血流感染的发生率
J Burn Care Res. 2012 Jul-Aug;33(4):539-43. doi: 10.1097/BCR.0b013e31823c4cd5.

本文引用的文献

1
Multinational prospective study of incidence and risk factors for central-line-associated bloodstream infections in 728 intensive care units of 41 Asian, African, Eastern European, Latin American, and Middle Eastern countries over 24 years.在24年的时间里，对亚洲、非洲、东欧、拉丁美洲和中东41个国家的728个重症监护病房进行的中心静脉导管相关血流感染发病率和危险因素的多国前瞻性研究。
Infect Control Hosp Epidemiol. 2023 Apr 28:1-11. doi: 10.1017/ice.2023.69.
2
Management of Inadvertent Arterial Catheterization during Central Venous Catheter Placement: A Case Series.中心静脉导管置入过程中意外动脉插管的处理：病例系列
J Pers Med. 2022 Sep 19;12(9):1537. doi: 10.3390/jpm12091537.
3
Central venous catheter-related infection - back to basics.中心静脉导管相关感染——回归基础
Afr J Thorac Crit Care Med. 2022 May 5;28(1). doi: 10.7196/AJTCCM.2022.v28i1.244. eCollection 2022.
4
Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update.急性护理医院预防中心静脉导管相关血流感染的策略：2022年更新
Infect Control Hosp Epidemiol. 2022 May;43(5):553-569. doi: 10.1017/ice.2022.87. Epub 2022 Apr 19.
5
Prevalence of Central Line-Associated Bloodstream Infections (CLABSI) in Intensive Care and Medical-Surgical Units.重症监护病房及内科-外科病房中心静脉导管相关血流感染（CLABSI）的发生率
Cureus. 2022 Mar 3;14(3):e22809. doi: 10.7759/cureus.22809. eCollection 2022 Mar.
6
The Comparative Efficacy of Chlorhexidine Gluconate and Povidone-iodine Antiseptics for the Prevention of Infection in Clean Surgery: A Systematic Review and Network Meta-analysis.氯己定葡萄糖酸盐和聚维酮碘消毒剂预防清洁手术感染的比较疗效：系统评价和网络荟萃分析。
Ann Surg. 2021 Dec 1;274(6):e481-e488. doi: 10.1097/SLA.0000000000004076.
7
Surveillance of bloodstream infections in intensive care units in England, May 2016-April 2017: epidemiology and ecology.英格兰重症监护病房血流感染监测，2016 年 5 月-2017 年 4 月：流行病学和生态学。
J Hosp Infect. 2020 Sep;106(1):1-9. doi: 10.1016/j.jhin.2020.05.010. Epub 2020 May 16.
8
The 100 top-cited systematic reviews/meta-analyses in central venous catheter research: A PRISMA-compliant systematic literature review and bibliometric analysis.100 篇中心静脉导管研究中被引频次最高的系统评价/荟萃分析：一项符合 PRISMA 原则的系统文献回顾和文献计量学分析。
Intensive Crit Care Nurs. 2020 Apr;57:102803. doi: 10.1016/j.iccn.2020.102803. Epub 2020 Feb 5.
9
Pre- and post-review of a standardized ultrasound-guided central venous catheterization curriculum evaluating procedural skills acquisition and clinician confidence.对标准化超声引导下中心静脉置管课程进行前后评估，以评估操作技能的掌握情况和临床医生的信心。
J Vasc Access. 2020 Jul;21(4):440-448. doi: 10.1177/1129729819882602. Epub 2019 Nov 6.
10
The efficacy of a non-leaching antibacterial central venous catheter - a prospective, randomized, double-blind study.非浸出型抗菌中心静脉导管的疗效 - 一项前瞻性、随机、双盲研究。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Jun;164(2):154-160. doi: 10.5507/bp.2019.022. Epub 2019 May 28.

观察性、回顾性真实世界证据研究表明抗菌中央静脉导管的安全性、性能和有用性。

Observational, retrospective real-world evidence study demonstrates safety, performance and usefulness of antimicrobial central venous catheters.

机构信息

Teleflex Incorporated, Morrisville, NC USA.

出版信息

J Int Med Res. 2024 Sep;52(9):3000605241279236. doi: 10.1177/03000605241279236.

DOI:10.1177/03000605241279236
PMID:39308254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11425742/
Abstract

OBJECTIVE

To collect real-world data to demonstrate the safety and performance of Arrowg+ard Blue® /Arrowg+ard Blue Plus® (AGB/AGB+) central venous catheters (CVCs).

METHODS

This observational, retrospective study involved patients who required AGB/AGB+ CVCs at designated general hospitals in USA (22), UK (19) and Germany (2). Data were extracted from electronic medical records. There were no specific inclusion/exclusion criteria. Primary endpoint was successful treatment without an adverse event (AE). Secondary endpoint was rate of AEs.

RESULTS

In total, 384 cases were included from 43 centres and most patients (74%) were >35 years of age. A success rate of 99%, and an overall AE rate of 0.8% were observed. Moreover, the overall infection rate was lower than typically reported for standard catheters. In addition, power injection of contrast media was successful in all 51 cases.

CONCLUSIONS

This study indicates the AGB/AGB+ CVCs perform as intended with a high success rate and few AEs. Further large-scale, controlled studies are required to confirm our findings.

摘要

目的

收集真实世界的数据，以证明 Arrowg+ard Blue® / Arrowg+ard Blue Plus®（AGB/AGB+）中心静脉导管（CVC）的安全性和性能。

方法

这是一项观察性、回顾性研究，涉及在美国（22 个）、英国（19 个）和德国（2 个）指定的综合医院需要使用 AGB/AGB+ CVC 的患者。数据从电子病历中提取。没有特定的纳入/排除标准。主要终点是没有不良事件（AE）的成功治疗。次要终点是 AE 发生率。

结果

共纳入 384 例来自 43 个中心的病例，大多数患者（74%）年龄>35 岁。观察到成功率为 99%，总 AE 发生率为 0.8%。此外，总体感染率低于标准导管的典型报告。此外，在所有 51 例中，均成功进行了对比剂的动力注射。

结论

本研究表明，AGB/AGB+ CVC 按照预期进行操作，成功率高，AE 少。需要进一步进行大规模、对照研究来证实我们的发现。